Kevin Zablonski/LinkedIn, William Archibald/LinkedIn
Jul 23, 2026, 19:25
William Archibald: Key Takeaways on VTE Cost-Effectiveness and Cancer Associated Thrombosis from ISTH 2026
William Archibald, Assistant Professor of Medicine at Wilmot Cancer Institute, shared a post on LinkedIn:
“Back home in Rochester from a very successful International Society on Thrombosis and Haemostasis (ISTH) 2026 where Kevin Zablonski and I presented our work on the cost effectiveness of apixaban for extended prevention in provoked VTE (clinical benefit and cost effective from Medicare perspective!)
Look out for our highlights of ISTH 2026 coming to OncUpdates soon for practice changes in cancer associated thrombosis and thrombocytopenia
Looking forward to ISTH 2027 in Vancouver.”
-
Jul 23, 2026, 20:46Grace Choung: A Novel CFHR5 Copy Number Variant in Postpartum Atypical HUS
-
Jul 23, 2026, 20:10Mohammad Alzoubi: One Month of Dual Antithrombotic Therapy After PCI Was Non-Inferior to 12 Months
-
Jul 23, 2026, 20:08Ahmed Bennis: Calcitriol Replenishment May Mitigate Ischemic Risk in MASLD
-
Jul 23, 2026, 20:06Mitsuaki Sawano: Can Cardiovascular Risk Prediction Models Developed in One Population be Reliably Applied to Another?
-
Jul 23, 2026, 20:05Abdul Muqtadir Abbasi: Hemostasis Isn’t About Memorizing Factor Numbers – It’s About Recognizing Patterns
-
Jul 23, 2026, 19:40Maureen Macharia: How Apixaban Transformed Modern Anticoagulation
-
Jul 23, 2026, 19:30Jordan Agay: Why We Need to Track the Neurological Costs of Anemia
-
Jul 23, 2026, 19:17Diego López Santos: Donation after Donation, I Just Reached 100
-
Jul 23, 2026, 19:11Jecko Thachil: Chlorosis May Have Represented Iron Deficiency in the 19th Century